157 related articles for article (PubMed ID: 34819271)
1. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease.
Simon D; Tascilar K; Fagni F; Schmidt K; Krönke G; Kleyer A; Ramming A; Schoenau V; Bohr D; Knitza J; Harrer T; Manger K; Manger B; Schett G
Ann Rheum Dis; 2022 Jul; 81(7):1023-1027. PubMed ID: 34819271
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders.
Ammitzbøll C; Kragh Thomsen M; Bøgh Andersen J; Jensen JMB; From Hermansen ML; Dahl Johannsen A; Larsen ML; Mistegaard CE; Mikkelsen S; Szabados F; Vils SR; Erikstrup C; Hauge EM; Troldborg A
Rheumatology (Oxford); 2023 Jul; 62(7):2544-2549. PubMed ID: 36445008
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
4. B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab.
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Jahrsdörfer B; Schrezenmeier H; Ludwig C; Sattler A; Kotsch K; Chen Y; Claußnitzer A; Haibel H; Proft F; Guerra G; Durek P; Heinrich F; Ferreira-Gomes M; Burmester GR; Radbruch A; Mashreghi MF; Lino AC; Dörner T
Arthritis Rheumatol; 2022 Jun; 74(6):934-947. PubMed ID: 34962360
[TBL] [Abstract][Full Text] [Related]
5. Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial.
Bonelli M; Mrak D; Tobudic S; Sieghart D; Koblischke M; Mandl P; Kornek B; Simader E; Radner H; Perkmann T; Haslacher H; Mayer M; Hofer P; Redlich K; Husar-Memmer E; Fritsch-Stork R; Thalhammer R; Stiasny K; Winkler S; Smolen JS; Aberle JH; Zeitlinger M; Heinz LX; Aletaha D
Ann Rheum Dis; 2022 May; 81(5):687-694. PubMed ID: 35027397
[TBL] [Abstract][Full Text] [Related]
6. Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients.
Ammitzbøll C; Thomsen MK; Andersen JB; Jensen JMB; Bayarri-Olmos R; Garred P; Hermansen MF; Johannsen AD; Larsen ML; Mistegaard CE; Mikkelsen S; Nielsen L; Olesen R; Pérez-Alós L; Vils SR; Szabados F; Søgaard OS; Tolstrup M; Erikstrup C; Hauge EM; Troldborg A
Clin Exp Rheumatol; 2024 Jan; 42(1):157-165. PubMed ID: 37877429
[TBL] [Abstract][Full Text] [Related]
7. Persistent but atypical germinal center reaction among 3
Stefanski AL; Rincon-Arevalo H; Schrezenmeier E; Karberg K; Szelinski F; Ritter J; Chen Y; Meisel C; Jahrsdörfer B; Ludwig C; Schrezenmeier H; Lino AC; Dörner T
Front Immunol; 2022; 13():943476. PubMed ID: 36032111
[TBL] [Abstract][Full Text] [Related]
8. Impact of rituximab on humoral response to SARS-CoV-2 vaccination in previously vaccinated patients with autoimmune diseases.
Oliosi E; Flahault A; Charre C; Veyer D; Combier A; Lafont E; Karras A; Mouthon L; Avouac J; Terrier B; Hadjadj J
Clin Rheumatol; 2023 Sep; 42(9):2485-2490. PubMed ID: 37243801
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
[TBL] [Abstract][Full Text] [Related]
10. High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients.
Fabris M; De Marchi G; Domenis R; Caponnetto F; Guella S; Dal Secco C; Cabas N; De Vita S; Beltrami AP; Curcio F; Quartuccio L
J Autoimmun; 2022 May; 129():102827. PubMed ID: 35427999
[TBL] [Abstract][Full Text] [Related]
11. Analysis of factors involved in the development of humoral response to vaccination against SARS-CoV-2 in patients with rheumatic pathology under biological treatment.
Flores-Fernández E; Vázquez-Gomez I; Valls-Pascual E; Valera-Ribera C; Andújar-Brazal P; Alegre-Sancho JJ
Reumatol Clin (Engl Ed); 2023 Dec; 19(10):565-570. PubMed ID: 38008603
[TBL] [Abstract][Full Text] [Related]
12. Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study.
Koehm M; Klippstein M; Dauth S; Hallmann K; Kohmer N; Burkhardt H; Ciesek S; Geisslinger G; Rabenau HF; Behrens F
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37652553
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.
Avouac J; Miceli-Richard C; Combier A; Steelandt A; Fogel O; Mariaggi AA; Meritet JF; Rozenberg F; Molto A; Allanore Y
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI163-SI168. PubMed ID: 34726701
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
15. Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy.
Sidler D; Born A; Schietzel S; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Seyed Jafari SM; Radonjic-Hoesli S; Chan A; Hoepner R; Bacher U; Mani LY; Iype JM; Suter-Riniker F; Staehelin C; Nagler M; Hirzel C; Maurer B; Moor MB
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35361691
[TBL] [Abstract][Full Text] [Related]
16. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis.
van der Togt CJT; Ten Cate DF; van den Bemt BJF; Rahamat-Langendoen J; den Broeder N; den Broeder AA
Rheumatology (Oxford); 2023 Apr; 62(4):1627-1630. PubMed ID: 36000861
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.
Saleem B; Ross RL; Bissell LA; Aslam A; Mankia K; Duquenne L; Corsadden D; Carter C; Hughes P; Nadat FA; Mulipa P; Lobb M; Clarke B; Mbara K; Morton R; Dibb S; Chowdhury R; Newton D; Pike A; Kakkar V; Savic S; DelGaldo F; Emery P
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35365569
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease.
Haberman RH; Herati RS; Simon D; Samanovic M; Blank RB; Tuen M; Koralov SB; Atreya R; Tascilar K; Allen JR; Castillo R; Cornelius AR; Rackoff P; Solomon G; Adhikari S; Azar N; Rosenthal P; Izmirly P; Samuels J; Golden B; Reddy S; Neurath M; Abramson SB; Schett G; Mulligan MJ; Scher JU
medRxiv; 2021 May; ():. PubMed ID: 34013285
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE).
Tran AP; Tassone D; Nossent J; Ding NS
RMD Open; 2022 May; 8(1):. PubMed ID: 35577478
[TBL] [Abstract][Full Text] [Related]
20. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
